Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101
CERULEAN PHARMA (NASDAQ: CERU) Delayed: 0.66 --0 (-0%)
Previous Close $0.66    52 Week High $4.33 
Open $8.29    52 Week Low $0.63 
Day High $0.66    P/E N/A 
Day Low $0.66    EPS $0.00 
Volume 97,258